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ABSTRACT   
Purpose of review. One of the seven key scientific priorities indentified in the road map on HIV cure 
research is to “determine host mechanisms that control HIV replication in the absence of therapy”. 
This review summarizes recent work in genomics and in epigenetic control of viral replication that is 
relevant for this mission.  
Recent findings. New technologies allow the joint analysis of host and viral transcripts. They identify 
the patterns of antisense transcription of the viral genome, and its possible role in gene regulation. 
High throughput studies facilitate the assessment of features of integration at the genome level. 
Integration site, orientation and host genomic context modulate transcription and should also be 
assessed at the level of single cells. The various models of latency in primary cells can be followed 
using dynamic study designs to acquire transcriptome and proteome data of the process of entry, 
maintenance and reactivation of latency. Dynamic studies can also be applied to the study of 
transcription factors and chromatin modifications in latency and upon reactivation.   
Summary. The convergence of primary cell models of latency, new high throughput quantitative 
technologies applied to the study of time series, and the identification of compounds that reactivate 
viral transcription brings unprecedented precision to the study of viral latency. 
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Introduction 
The global scientific strategy of the International HIV Society “Towards an HIV cure” [1] identified the potential 
of genomics for the understanding of mechanisms of latency. This includes the analysis of the steps in the 
establishment of viral transcriptional silencing as well as the steps that allow reactivation of viral transcription: 
the site of viral DNA integration, the chromatin environment of the integrated provirus and the availability of 
transcription factors. These components can be investigated through genomic, transcriptomic and epigenomic 
analyses.  
Currently, two models are used to describe how HIV establishes latency in resting CD4+ T cells [2, 3]. The first 
model suggests that activated cells are first infected by HIV, and even though the majority of them are 
productively infected and die within a few days, a minority of them revert to a resting memory state, following 
the natural biology of CD4+ T cells. Although the mechanisms leading to cell memory are yet unclear, it is 
accompanied by cellular changes at the transcriptome and proteome levels (that are yet to be completely 
described), that in turn impact the viral transcription, ultimately repressing it. The second model suggests that, 
even if poorly efficient, HIV is able to directly infect resting CD4+ T cells. Initial studies on HIV latency used 
different models based on cell lines, as primary cell cultures were difficult and short-lived. However, in the 
recent years, multiple models using primary cells - based on different CD4+ T cell populations - have been 
developed that yield sufficient amounts of cells, thereby allowing investigation that recapitulate events that 
may occur in vivo [4].  
Latency models using T cell lines and primary CD4+ T cells are also used for the screening and assessment of 
molecules that promote viral transcription [5-8]. That multiple compounds reactivate viral transcription from 
latently infected cells in vitro may reflect the various mechanisms involved in viral transcriptional control [6, 9]. 
These include epigenetic regulation (such as histone acetylation and DNA methylation) and immune 
modulation (such as T cell receptor engagement and protein kinase C signaling) [6, 9]. Some of the agents are 
moving forward to clinical assessment [1, 9, 10]. 
This review will present new aspects and opportunities in the use of novel technology for the analysis of 
contribution of host factors to the viral life cycle in productive infection, and of viral integration site and host 
factors (including epigenetic control of the viral promoter) in the establishment of and reactivation from 
latency (Figure 1).  
Dynamic aspects of the viral life cycle 
HIV-1 is fully dependent of the cellular machinery to complete the replication cycle. The infected cell undergoes 
a profound modification of its physiology. Although the interaction  between HIV-1 and the host cell has been 
extensively studied [11], previous analyses did not assess all relevant steps of viral replication in a dynamic 
perspective. Transcriptome analyses used microarray technology in cross-sectional experiments, generally at 
the completion of the viral replication cycle (24-48 hours) [12]. The transcriptional status of genes contributes 
to preferential integration of proviruses [13]; however, there is limited data on how the viral integration 
contributes to host transcription at genome-wide level. Analyses have also been hampered by the 
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heterogeneity of the infectious system, where the transcriptome profile reflects contribution by the infected 
and uninfected cells. Recent studies have approached this problem by magnetic sorting of cells infected in vitro 
identified by a marker recombinant protein that is expressed during the late-phase of viral replication cycle 
[14].  
Progress in deep-sequence technologies now allow the assessment of viral and host transcripts jointly. 
Lefebvre et al. [15] infected SupT1 cells to analyze cellular and viral transcriptomes by serial analysis of gene 
expression followed by highthroughput sequencing. At 24 hours post-infection, read mapping resulted in 33 to 
44 million tags aligning with the human transcriptome and 0.23 to 0.25 million tags aligning with the genome of 
the HIV-1 vector. Thus, at peak infection, 1 transcript in 143 is of viral origin (0.7%). Analysis also identified a 
small component of antisense viral transcription. Antisense transcription from the 3’LTR has been described in 
infected primary cells, including monocyte-derived cells and activated T lymphocytes [16].  
Kobayashi-Ishihara et al. [17] identified a 2.6 kb RNA as the major form of HIV-1 antisense RNAs. This transcript 
corresponds to the previously reported antisense protein (ASP) mRNA. The expression of this antisense RNA 
suppressed HIV-1 replication and its knockdown enhanced HIV-1 gene expression and replication. Schopman et 
al. [18] detected numerous small RNAs encoded by the HIV-1 genome. Most sequences have positive polarity 
and could correspond to viral miRNAs. A small portion of the viral small RNAs have negative polarity and they 
could represent viral siRNAs. Importantly, the identified viral siRNAs potently repress HIV-1 production. The 
authors proposed that these short virally encoded miRNAs and siRNAs modulate cellular and/or viral gene 
expression. 
More recently, the complete dynamic profile of viral replication intermediates, host small RNAs and mRNAs has 
been captured and modeled [19]. A significant proportion of host genes are modulated in concordance with 
key steps of viral cycle. Analyses underscored the features of the successful viral replication occurring despite a 
profound perturbation of the cell at the transcriptional level. This type of work – currently performed in cell 
lines - represents a referential resource that can be contrasted across cellular systems and viral strains, and 
that can be extended to study the establishment of and reactivation from viral latency.  
Spatial features of HIV integration 
HIV inserts its viral genome non-randomly into the host DNA, strongly favoring active transcription units, 
thereby potentially promoting efficient viral transcription and productive infection [13, 20]. However, the 
location of the viral genome may also hamper viral transcription and thereby promote latency. To date, the site 
of viral integration has been shown to contribute to viral repression mostly by the following mechanisms: (i) 
the chromatin environment may disfavor viral transcription: viral genomes integrated into centromeric alphoid 
repeats or in gene deserts (although representing a minority of integration sites compared to active 
transcription units) are more prone to heterochromatin formation and thus more likely to be associated with 
viral transcriptional repression, as shown in a cell line model of latency and in a model of direct infection of 
resting primary CD4+ T cells [21-24]; and (ii) viral genome integration in active transcription units imply that 
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transcription of cellular genes flanking the proviral genome may lead to transcriptional interference through 
promoter occlusion or collision, thereby potentially resulting in viral transcription repression: highly expressed 
genes hosting integrated viral genomes lead to reduction of viral transcription in a cell line model of latency 
and in resting primary CD4+ T cells [23, 25]. Analysis of viral transcription performed upon targeted insertion of 
the viral genome in one actively transcribed gene (HPRT) suggested that viral transcription was inhibited when 
viral and cellular transcription were in convergent orientations whereas it was enhanced when viral and cellular 
transcription were in the same orientation [26]. In contrast, in a primary CD4+ T cell model of latency, viral 
integration in the same orientation as cellular hosting genes was enriched in latent cells, suggesting that 
repression of viral transcription was preferentially promoted upon promoter occlusion in this system [27]. 
These data argue for a contribution of integration site location and surrounding host genomic features to viral 
transcription efficiency; however to which extent each of these factors influences latency remains to be 
clarified. Diversity in integration site may also modulate the efficacy of reactivating agents used in in vitro 
models of latency [6, 9, 28]. 
In addition to the multiple ways by which HIV integration site location and orientation can contribute to 
latency, various CD4+ T populations have a different capacity to support the reservoir of HIV infection. These 
may result in significant loss of homogeneity in the population of latently infected cells, emphasizing the 
interest of examining cell-to-cell heterogeneity in single cell assays. There are now different techniques that 
make use of microfluidic platforms and highly multiplexed assays that allow the analysis of expression of 20 – 
800 genes at the single cell level [29, 30]. Progress in single cell analysis could allow a more precise evaluation 
of the influence of viral genome integration site on viral transcription. 
Transcriptome and proteome modifications during latency and reactivation 
Some of the recent applications of transcriptome analysis aimed at the characterization of the pattern of host 
expression after control of viral replication in vivo [12, 31, 32]. Similar approach was applied to the 
characterization of host expression profile in elite controllers. The transcriptome profile in CD4+ T cells of 
successfully treated individuals becomes similar to that of elite controllers. Detailed analysis of specific cell 
subsets may however demonstrated residual abnormalities in gene regulation among individuals receiving 
antiretroviral treatment compared with healthy blood donors [33]. These analyses however capture population 
effects that reflect overall consequences of immune activation and the contribution of transcriptomes of non-
infected cells.    
Comparison of resting and activated CD4+ T cell transcriptomes identified differentially expressed and 
alternatively spliced genes [34-36]. Of note, these studies used resting cells, and then stimulated them to 
activated cells; however, no study describes the contrary, i.e. activated to resting. Assessing transcriptome 
changes from activated infected cells to resting cells is needed to better characterize the sequence of events 
leading to viral transcriptional silencing.  
Resting and activated CD4+ T cells also differ in their proteome composition. Although no large-scale proteome 
study was performed so far to compare CD4+ T cells in these two states, the differential expression or 
localization of specific proteins has been reported. More particularly, the pool of available transcription factors 
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in the nucleus regulating viral transcription varies between resting and activated CD4+ T cells [4, 37]. Examples 
include (i) the nuclear availability of NF-κB in activated cells while sequestered in the cytoplasm of quiescent 
CD4+ T cells, (ii) the high amount of CBF-1, an inhibitor of LTR-driven viral transcription, in resting cells while 
reduced amounts were detected in activated cells [37, 38], (iii) the degradation of cyclinT1 and the absence of 
T186 phosphorylation on cdk9, the units composing pTEFb kinase, in resting cells while abundantly present in 
activated cells [39].  
Epigenetic modifications of the HIV promoter  
As the viral genome is integrated into the host DNA, it is chromatinized and subject of cellular epigenetic 
regulation. Chromatin organization at the viral LTR promoter has been investigated, identifying precisely 
positioned nucleosomes [40, 41]: nuc-0 at position -415 to -255 (compared to Transcriptional Start Site, TSS, 
+1), a nucleosome-free region or with poorly positioned nucleosomes (-255 to -3/+10), nuc-1 at +10 to +155, a 
nucleosome-free region (+155 to +265), and nuc-2 at +265- to +409.  Nucleosome-free regions present binding 
sites for multiple transcriptional regulators, while nuc-1 is positioned just after the TSS, blocking viral 
transcription, and thus needed to be displaced or disrupted to allow successful transcriptional elongation. Thus, 
the identity of bound transcriptional regulators as well as histone post-translational modifications and DNA 
methylation will dictate viral gene expression [4]. 
Binding of available specific transcription factors recruit chromatin modifying enzymes that will shape the 
chromatin environment at the viral LTR and participate in regulation of viral transcription activity. Studies using 
chromatin immunoprecipitation (ChIP) showed that histone post-translational modifications, specifically 
acetylation and methylation, are correlated with viral transcriptional activity [4, 41-43]. DNA methylation in the 
CpG islands surrounding the viral transcription start site is associated with viral gene silencing [3, 44, 45]. DNA 
methylation is currently described as being the last step of repression of gene expression, contributing to a 
compact chromatin structure and decreasing the efficiency of some reactivating agents. These data confirmed 
that specific transcription factors, histone modifications and DNA methylation levels at the viral promoter 
determine the efficiency of viral gene expression. However, most of these studies compared activated vs 
resting cells at one single time point focusing on specific histone post-translational modifications, without 
sequential evaluation of chromatin modifications. 
Conclusions 
Genomic analyses are well suited for the study of viral latency and reactivation as a dynamic process. As such, 
these approaches respond to several of the priorities of the HIV Cure Research agenda published in 2012 [1] 
(Box 1); in particular the call for detailed understanding of the transcriptional features of the process of 
latency, and the possibility to use novel technologies. Specific issues where novel technology may be of 
importance include assessment of (i) the extent of “true” latency, i.e. the degree of HIV transcriptional silence, 
(ii) the role of spatial features of viral integration contributing to transcription, (iii) the identification of 
candidate biomarkers of latency, and (iv) the characterization of successful activation programs leading to viral 
expression at population and single cell level. Keypoints are presented in Box 2. 
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Keypoints.  
 
• New technologies have been employed for the quantitative, dynamic analyses of viral-host 
interaction: RNA sequencing, proteome analysis, ChIP sequencing. 
• The first models of productive and latent infection are generated using cell lines and primary 
CD4 + T cell. 
• There is increasing recognition of the role of antisense transcription of the HIV genome in 
regulating viral gene expression.  
• Integration site, orientation, and surrounding host genetic features influence viral 
transcription efficiency. 
• Single cell analysis will be needed to assess the role of integration features on viral 
transcription, and other aspects of heterogeneity in the latent cell population. 
 
Figure 1. Schematic overview of tools and technologies for the study of latency. Recent 
developments in cellular models of latency, and increasing performance of high-throughput studies 
pave the way to a detailed description of the sequential steps leading to repression of viral 
transcription.   
 
Figure 2. Recommendations from the International AIDS Society Scientific Working Group on HIV 
Cure, Towards an HIV Cure on the use of novel technologies in latency research.   (A Global 
Scientific Strategy, Full Recommendations Report”, July 19, 2012, www.iasociety.org) 
 
1. Parallel assessment of existing in vitro latency models and patient derived latently infected 
cells. Some potential approaches include: 
a. Deep-sequencing of latently infected cells – using latently infected cells from in vitro 
models and patient derived cells. 
b. Validation of the phenotype/expression profile of the latently infected cell. This 
includes testing of “expression modules” (short list of genes associated with the 
study profile), and development of single cell assays. 
2. Characterization of viral transcripts (if any) associated with latency, or with entry/exit from 
latency – including antisense transcripts with a possible regulatory role. 
3. Clinical and biological determinants of reservoir size. This could first be assessed using large 
well characterized cohort studies comparing reservoir size to a range of clinical parameters. 
The use of genomics, transcriptomics and other population based approaches should also be 
considered. 
4. Adaptation of identified candidate markers for high throughput screening (FACS, gene 
expression assays). 
5. Identification of host factors that determine the size of the reservoir. 
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